22 April 2022 
EMA/CHMP/691024/2021 Rev.2 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Tecfidera 
dimethyl fumarate 
On 22 April 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Tecfidera.2 
The marketing authorisation holder for this medicinal product is Biogen Netherlands B.V. 
The CHMP adopted an extension to the existing indication as follows:  
Treatment  of  paediatric  patients  aged  13 years  and  older  with  relapsing  remitting  multiple 
sclerosis (RRMS).  
For information, the full indications for Tecfidera will be as follows3: 
Tecfidera is indicated for the treatment of adult and paediatric patients with relapsing remitting 
multiple sclerosis (see section 5.1 for important information on the populations for which efficacy 
has been established) aged 13 years and older with relapsing remitting multiple sclerosis 
(RRMS).  
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report (EPAR) 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 The CHMP had initially adopted an opinion on 27 January 2022. Following a re-examination of the initial opinion at the 
request of the marketing authorisation holder, the CHMP readopted its opinion on 22 April 2022. 
3 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
